Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study to Evaluate the Cardiac Safety of Two Doses of Glycopyrrolate Bromide (25 microG AND 50 microG BID) Delivered Via HFA PMDI Both Combined with Foster 100/6 microG BID Delivered Via HFA PMDI Versus Foster 100/6 microG BID Delivered Via HFA PMDI in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

Next Previous
Trial Profile

Randomised, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study to Evaluate the Cardiac Safety of Two Doses of Glycopyrrolate Bromide (25 microG AND 50 microG BID) Delivered Via HFA PMDI Both Combined with Foster 100/6 microG BID Delivered Via HFA PMDI Versus Foster 100/6 microG BID Delivered Via HFA PMDI in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms CARSAF

    • Most Recent Events

    • 09 Oct 2012 Planned end date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
    • 24 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Planned end date changed from 29 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top